Pharma companies escape bitter pill, for now
The Trump administration's decision to exempt tariffs on Indian pharma imports brings relief to a $9 billion-plus US export market, highlighting India's key role in providing affordable generic medicines. However, India's medical device sector faces a 26% reciprocal tariff, potentially impacting its growth and exports.
The Trump administration's decision to exempt tariffs on Indian pharma imports brings relief to a $9 billion-plus US export market, highlighting India's key role in providing affordable generic medicines. However, India's medical device sector faces a 26% reciprocal tariff, potentially impacting its growth and exports.
